» Articles » PMID: 16076473

A Sensitive Flow Cytometry-based Cytotoxic T-lymphocyte Assay Through Detection of Cleaved Caspase 3 in Target Cells

Overview
Publisher Elsevier
Date 2005 Aug 4
PMID 16076473
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

We describe a highly sensitive flow cytometry-based CTL assay using the cleavage of caspase 3 in target cells as a readout. The assay involved labeling of cells with a cell tracker dye and staining permeabilized cells with an antibody recognizing cleaved caspase 3. The assay proved to be robust and reliable in measuring antigen-specific CTL activity in a number of human and murine systems, including MLR, human peptide-specific T-cell responses induced in vitro, and CTL responses following immunization of mice with viral and peptide vaccines. The assay was found to yield comparable results as 51Cr-release, but with markedly higher sensitivity. When compared to detection of antigen-specific T cells via HLA tetramer/pentamer-based methods of T-cell staining in HIV gag peptide-specific human T cell lines the caspase 3 cleavage readout assay exhibited a comparable level of sensitivity with detection of CTL function at antigen-specific T-cell frequencies of 1:15,000 or lower. A similar level of sensitivity was obtained when murine CTL assays were performed with MLR in which effector cells were highly diluted with naïve syngeneic spleen cells. Our results indicate that the caspase 3 cleavage assay may be a powerful tool to measure antigen-specific CTL responses in human vaccine trials and in pre-clinical animal models of CTL function at both high and low effector cell frequencies.

Citing Articles

beta-cell killing models using immune cells and human pluripotent stem cell-derived islets: Challenges and opportunities.

Halliez C, Ibrahim H, Otonkoski T, Mallone R Front Endocrinol (Lausanne). 2023; 13:1076683.

PMID: 36726462 PMC: 9885197. DOI: 10.3389/fendo.2022.1076683.


Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma.

Cichocki F, Bjordahl R, Goodridge J, Mahmood S, Gaidarova S, Abujarour R Nat Commun. 2022; 13(1):7341.

PMID: 36446823 PMC: 9709157. DOI: 10.1038/s41467-022-35127-2.


In vitro naphthylquinoxaline thymidine conjugate and UVA treated cancer cells are effective therapeutic vaccines for tumors in vivo with CpG as the adjuvant.

Yang R, Zhou S, Zhou Q J Adv Res. 2022; 35:259-266.

PMID: 35003803 PMC: 8721236. DOI: 10.1016/j.jare.2021.03.003.


Co-delivery of novel bispecific and trispecific engagers by an amplicon vector augments the therapeutic effect of an HSV-based oncolytic virotherapy.

Ravirala D, Mistretta B, Gunaratne P, Pei G, Zhao Z, Zhang X J Immunother Cancer. 2021; 9(7).

PMID: 34230110 PMC: 8261877. DOI: 10.1136/jitc-2021-002454.


The Glutaminase Inhibitor CB-839 (Telaglenastat) Enhances the Antimelanoma Activity of T-Cell-Mediated Immunotherapies.

Varghese S, Pramanik S, Williams L, Hodges H, Hudgens C, Fischer G Mol Cancer Ther. 2020; 20(3):500-511.

PMID: 33361272 PMC: 7933078. DOI: 10.1158/1535-7163.MCT-20-0430.